Edition:
United States

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

149.11USD
26 May 2017
Change (% chg)

-- (--)
Prev Close
$149.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
313,639
52-wk High
$192.94
52-wk Low
$36.74

TSRO.OQ

Chart for TSRO.OQ

About

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $8,031.77
Shares Outstanding(Mil.): 53.86
Dividend: --
Yield (%): --

Financials

  TSRO.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -8.40 -- --
ROI: -92.31 -8.48 -5.42
ROE: -128.52 -11.31 -4.68

BRIEF-Tesaro reports Q1 loss per share $2.55

* Q1 earnings per share view $-2.24 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

May 09 2017

BRIEF-TESARO submits investigational new drug application for TSR-033 to U.S. FDA

* TESARO announces submission of investigational new drug application for anti-lag antibody tsr-033 to the u.s. Fda

May 01 2017

BRIEF-Tesaro initiates registrational development program for anti-pd-1 antibody TSR-042

* Tesaro initiates registrational development program for anti-pd-1 antibody tsr-042

Apr 27 2017

BRIEF-Tesaro announces approval of Varuby by European Commission

* Tesaro announces approval of Varuby® (oral rolapitant tablets) by European Commission

Apr 26 2017

BRIEF-Tesaro selects US Bioservices as specialty pharmacy partner for Zejula

* US Bioservices says has been selected by Tesaro, Inc as a specialty pharmacy partner for Zejula Source text for Eikon: Further company coverage:

Apr 19 2017

BRIEF-Diplomat Pharmacy says will dispense Tesaro's cancer drug

* Diplomat Pharmacy Inc says will dispense zejula to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Apr 19 2017

BRIEF-TESARO announces availability of ovarian cancer drug in U.S.

* TESARO announces availability of zejula™ (niraparib) for patients with recurrent ovarian cancer in the U.S.

Apr 19 2017

BRIEF-Tesaro CEO 2016 total compensation was $5.7 mln

* CEO Leon Moulder Jr's 2016 total compensation was $5.7 million versus $5.5 million in 2015 - SEC filing Source text: (http://bit.ly/2oMgYGz) Further company coverage:

Apr 07 2017

Indian shares recover broadly on global cues; financials lead gains

* Bharti Infratel surges after stake purchase by PE investors

Mar 28 2017

UPDATE 1-FDA approves Tesaro's ovarian cancer drug

March 27 The U.S. Food and Drug Administration on Monday approved Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.

Mar 27 2017

More From Around the Web

Earnings vs. Estimates